Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback